Oxford Biomedica and Institut Mérieux enter into exclusive negotiations for the proposed acquisition of ABL Europe

Oxford Biomedica, a leading quality and innovation-led cell and gene therapy CDMO (“Contract Development Manufacturing Organisation”) and Institut Mérieux announce that they have entered into exclusive negotiations concerning Oxford Biomedica’s proposed acquisition of ABL Europe, a Group’s company specialized in viral vector development and manufacturing.